GLYSET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GLYSET (GLYSET).
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
| Metabolism | Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug). |
| Excretion | Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%). |
| Half-life | Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 mL/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease). |
| Protein binding | Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding. |
| Bioavailability | Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut. |
| Onset of Action | Oral administration: Onset of action is within 1-2 hours, with peak effect on postprandial glucose reduction at approximately 1-2 hours after a meal. |
| Duration of Action | Duration of action is approximately 4-6 hours after a single oral dose, corresponding to the inhibition of intestinal alpha-glucosidases during carbohydrate digestion. Clinical note: The drug is administered with the first bite of each main meal to cover postprandial hyperglycemia. |
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if GFR < 25 mL/min/1.73 m². No adjustment needed for GFR ≥ 25 mL/min/1.73 m². |
| Liver impairment | No specific guidelines; use caution in Child-Pugh class B or C due to limited data. |
| Pediatric use | Not recommended for pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GLYSET (GLYSET).
| Breastfeeding | Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants. |
| Teratogenic Risk | Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed. |
| Fetal Monitoring | Monitor blood glucose and HbA1c; assess for GI side effects; fetal ultrasound for growth if maternal diabetes poorly controlled. |
■ FDA Black Box Warning
None
| Serious Effects |
["Diabetic ketoacidosis","Inflammatory bowel disease","Colonic ulceration","Partial intestinal obstruction","Predisposition to intestinal obstruction","Chronic intestinal diseases associated with marked disorders of digestion or absorption","Cirrhosis","Hypersensitivity to miglitol"]
| Precautions | ["Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose)","Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon","Hepatotoxicity (rare, monitor liver enzymes)","May cause loss of glycemic control if used with intestinal disorders"] |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility in animal studies; limited human data. |